Clinical Trial

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-10-30; most recent amendment 2026-04-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-13
Trial Details
NCT Number NCT06669572
Lead Sponsor University of Chicago
Conditions Carcinoma, Squamous Cell, Anorectal Cancer
Enrollment 35 participants
Start Date 2025-07-11
Primary Completion 2029-03-26 (estimated)
Study Completion 2029-03-26 (estimated)
Updated on ClinicalTrials.gov 2026-04-15